亞盛醫藥(06855.HK)抗耐藥白血病新藥臨床進展再入選美國血液學會年會口頭報告
亞盛醫藥(06855.HK)公布,公司的原創1類新藥新型BCR-ABL抑制劑HQP1351(擬定中文通用名:奧瑞巴替尼)的關鍵性註冊II期臨床研究結果入選第62屆美國血液學會(American Society of Hematology (ASH))年會的口頭報告。
北京大學人民醫院血液科兩教授黃曉軍和江倩是研究的主要研究者,江倩將在會議期間作此報告。這是繼2018、2019年之後,HQP1351的臨床進展第三次入選ASH年會口頭報告。連續三年入選,充分顯示了國際血液學界對HQP1351療效和安全性的認可。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.